GlassScriptPhysician profile
Todd J Adams
NPI 1477585107
$7,441.86
in general payments reported to CMS, 2019-2025
59 companies · $623 in 2025
The $623 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $953 · 2020: $998 · 2021: $1,346 · 2022: $1,650 · 2023: $1,149 · 2024: $722 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,338 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,337.77 |
| Education | $156.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,022.30 | 2019-2025 | Orilissa, Liletta, Lo Loestrin Fe |
| Novo Nordisk INC | $739.42 | 2019-2025 | Wegovy, Saxenda |
| Avion Pharmaceuticals | $575.27 | 2019-2023 | Balcoltra |
| Pfizer INC. | $504.51 | 2019-2025 | |
| Merz North America, INC. | $416.40 | 2019-2022 | |
| Astellas Pharma US INC | $346.48 | 2019-2025 | Veozah |
| Mayne Pharma Commercial LLC | $271.62 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $267.36 | 2022 | |
| Therapeuticsmd, INC. | $239.51 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $221.28 | 2023-2025 | Myfembree |
| Exeltis, USA INC. | $213.48 | 2019-2025 | Slynd |
| Caldera Medical, INC | $197.00 | 2022-2023 | Desara |
| Bayer Healthcare Pharmaceuticals INC. | $170.24 | 2019-2023 | |
| Millicent US INC | $148.84 | 2024-2025 | Femring, Intrarosa, Femlyv |
| Biohaven Pharmaceuticals, INC. | $141.53 | 2020-2021 |
Show all 58 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.